Cover Image

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

Selinexor is an oral, selective nuclear export inhibitor. STORM was a phase 2b, single-arm, open-label, multicenter trial of selinexor with low dose dexamethasone in patients with penta-exposed relapsed/refractory multiple myeloma (RRMM) that met its primary endpoint, with overall response of 26% (9...

Full description

Saved in:
Bibliographic Details
Main Authors: Tremblay, Gabriel (Author) , Daniele, Patrick (Author) , Breeze, Janis (Author) , Li, Lingling (Author) , Shah, Jatin (Author) , Shacham, Sharon (Author) , Kauffman, Michael (Author) , Engelhardt, Monika (Author) , Chari, Ajaj (Author) , Nooka, Ajay (Author) , Vogl, Dan (Author) , Gavriatopoulou, Maria (Author) , Dimopoulos, Meletios-Athanasios (Author) , Richardson, Paul (Author) , Biran, Noa (Author) , Siegel, David (Author) , Vlummens, Philip (Author) , Doyen, Chantal (Author) , Facon, Thierry (Author) , Mohty, Mohamad (Author) , Meuleman, Nathalie (Author) , Levy, Moshe (Author) , Costa, Luciano (Author) , Hoffman, James E. (Author) , Delforge, Michel (Author) , Kaminetzky, David (Author) , Weisel, Katja (Author) , Raab, Marc-Steffen (Author) , Dingli, David (Author) , Tuchman, Sascha (Author) , Laurent, Frenzel (Author) , Vij, Ravi (Author) , Schiller, Gary (Author) , Moreau, Philippe (Author) , Richter, Joshua (Author) , Schreder, Martin (Author) , Podar, Klaus (Author) , Parker, Terri (Author) , Cornell, Robert Frank (Author) , Lionel, Karlin (Author) , Choquet, Sylvain (Author) , Sundar, Jagannath (Author)
Format: Article (Journal)
Language:English
Published: 06 September 2021
In: BMC cancer
Year: 2021, Volume: 21, Pages: 1-10
ISSN:1471-2407
DOI:10.1186/s12885-021-08453-9
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12885-021-08453-9
Verlag, lizenzpflichtig, Volltext: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08453-9
Get full text
Author Notes:Gabriel Tremblay, Patrick Daniele, Janis Breeze, Lingling Li, Jatin Shah, Sharon Shacham, Michael Kauffman, Monika Engelhardt, Ajaj Chari, Ajay Nooka, Dan Vogl, Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Paul Richardson, Noa Biran, David Siegel, Philip Vlummens, Chantal Doyen, Thierry Facon, Mohamad Mohty, Nathalie Meuleman, Moshe Levy, Luciano Costa, James E. Hoffman, Michel Delforge, David Kaminetzky, Katja Weisel, Marc Raab, David Dingli, Sascha Tuchman, Frenzel Laurent, Ravi Vij, Gary Schiller, Philippe Moreau, Joshua Richter, Martin Schreder, Klaus Podar, Terri Parker, Robert Frank Cornell, Karlin Lionel, Sylvain Choquet and Jagannath Sundar
Description
Summary:Selinexor is an oral, selective nuclear export inhibitor. STORM was a phase 2b, single-arm, open-label, multicenter trial of selinexor with low dose dexamethasone in patients with penta-exposed relapsed/refractory multiple myeloma (RRMM) that met its primary endpoint, with overall response of 26% (95% confidence interval [CI], 19 to 35%). Health-related quality of life (HRQoL) was a secondary endpoint measured using the Functional Assessment of Cancer Therapy - Multiple Myeloma (FACT-MM). This study examines impact of selinexor treatment on HRQoL of patients treated in STORM and reports two approaches to calculate minimal clinically important differences for the FACT-MM.
Item Description:Gesehen am 11.11.2021
Physical Description:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-021-08453-9

Similar Items